Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

The first medical treatment to use Crispr gene editing has been on the market for a year. Its complexity means few patients ...

CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This ...

From reprogrammed stem cells to next-generation gene editing, 2024 has seen some incredible developments with the potential to become new treatments.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

The new gene therapies for sickle cell disease—including the gene-editing treatment Casgevy, based on research at Boston ...

Alongside the FDA’s orphan drug designation in the U.S., the European Commission’s orphan medicinal product designation for mitapivat underscores the urgent need for novel therapies for sickle cell ...

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Cell and gene therapies are revolutionizing medicine. Looking to 2025, advancements in allogeneic therapies, streamlined ...

Drink milk, it helps keep muscles, bones, nerves, teeth, skiing and vision healthy. Milk reduces fatigue whilst maintaining ...